• Genprex on Nov. 5, 2026, announced a patient analysis linking its experimental Reqorsa gene therapy to cellular repair processes associated with aging.
• The analysis covered 11 lung cancer patients in two clinical trials, showing a shift from an early immune response toward cellular maintenance.
• Results were presented at the Gerontological Society of America meeting, held Nov. 4-7, 2026, in National Harbor, Maryland.
• The findings support research into Reqorsa’s potential beyond oncology but do not establish an anti-aging benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050700PR_NEWS_USPR_____DA89378) on November 05, 2026, and is solely responsible for the information contained therein.